go-v.orgdoi

Soluble form of a receptor for advanced glycation end products sRAGE as a biomarker

Sho‐ichi Yamagishi, Takanori Matsui · Frontiers in Bioscience-Elite · 2010

  • DOI 10.2741/e178
  • Publisher Frontiers Media
  • Type review
  • Issued 2010

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Frontiers in Bioscience-Elite · Frontiers Media · review · 2010

Abstract

There is a growing body of evidence that advanced glycation end products (AGEs) and their receptor (RAGE) system are implicated in various disorders, including vascular complications in diabetes, cardiovascular disease, neurodegenerative diseases, inflammatory and autoimmune disorders, and cancer growth and metastasis. Indeed, the engagement of RAGE with AGEs elicits oxidative stress generation and evokes inflammatory and thrombogenic responses, thus playing an important role in these devastating disorders.

Moreover, since administration of a recombinant soluble form of RAGE (sRAGE), has been shown to block the AGE-RAGE signaling pathway in animal models, exogenously administered sRAGE may capture and eliminate circulating AGEs, thus protecting against the AGE-elicited tissue damage by acting as a decoy receptor for AGEs. Recently, sRAGE has been identified in humans. However, there are a few comprehensive papers about the regulation and role of sRAGE in humans. Therefore, in this paper, we review the kinetics, regulation and pathophysiological role of sRAGE in humans. We further discuss the potential clinical utility of measuring sRAGE in various disorders as a biomarker.

Open the resolved locator · 10.2741/e178

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 02:29 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.2741/e178
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.